Cargando…

Fibrinolytic therapy for COVID-19: a review of case series

Detalles Bibliográficos
Autores principales:	Ji, Hong-Long, Dai, Yuling, Zhao, Runzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661828/ https://www.ncbi.nlm.nih.gov/pubmed/34893684 http://dx.doi.org/10.1038/s41401-021-00827-w

Ejemplares similares

Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians
por: Ji, Hong-Long, et al.
Publicado: (2021)

Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury
por: Liu, Cong, et al.
Publicado: (2018)

Systemic Fibrinolytic Therapy in the Presence of Absolute Contraindication; a Case Series
por: Pishgahi, Mahdi, et al.
Publicado: (2018)

Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC
por: Asakura, Hidesaku, et al.
Publicado: (2020)

COVID-19 in patients with HIV: clinical case series
por: Blanco, Jose L, et al.
Publicado: (2020)

Intrapleural Fibrinolytic Therapy With Alteplase for the Management of Multiloculated Malignant Pleural Effusion: A Case Series
por: Nemet, Marko, et al.
Publicado: (2022)

Takotsubo syndrome a rare entity in patients with COVID-19: An updated review of case-reports and case-series
por: Desai, Hardik D., et al.
Publicado: (2020)

A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients
por: Narula, Naureen, et al.
Publicado: (2021)

Fibrinolytic niche is required for alveolar type 2 cell-mediated alveologenesis via a uPA-A6-CD44(+)-ENaC signal cascade
por: Ali, Gibran, et al.
Publicado: (2021)

COVID-19–Associated Acute Kidney Injury: A Case Series
por: Patel, Niralee, et al.
Publicado: (2020)

ST-Segment Elevation in Patients with Covid-19 — A Case Series
por: Bangalore, Sripal, et al.
Publicado: (2020)

Intrapericardial Fibrinolytic Therapy in Purulent Pericarditis: A Review of Two Cases
por: Poudyal, Abhushan, et al.
Publicado: (2023)

Fibrinolytic Therapy in Acute Stroke
por: Millán, Mònica, et al.
Publicado: (2010)

Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis
por: Savioli, Felicio, et al.
Publicado: (2023)

Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
por: Nielsen, Nathan D., et al.
Publicado: (2022)

Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series
por: Armeni, Eleni, et al.
Publicado: (2020)

Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review
por: Barrett, Christopher D., et al.
Publicado: (2020)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis
por: Zhao, Runzhen, et al.
Publicado: (2017)

Trends and Outcomes of Fibrinolytic Therapy for STEMI: Insights and Reflections in the COVID-19 Era
por: Elbadawi, Ayman, et al.
Publicado: (2020)

Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
por: Haberman, Rebecca, et al.
Publicado: (2020)

Outcomes of COVID-19 in Pregnant Women with Sickle Cell Disease in India: A Case Series
por: Waghmare, Rakesh, et al.
Publicado: (2021)

Vaccine-Related Eruptions of Papules and Plaques Following COVID-19 Vaccination – A Case Series
por: Mohta, Alpana, et al.
Publicado: (2022)

The use of fibrinolytic therapy for parapneumonic effusion in pregnancy: a case report and a review
por: Nasralla, Awrad, et al.
Publicado: (2021)

COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
por: Luetic, Geraldine, et al.
Publicado: (2021)

Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series
por: Yang, Stephen Su, et al.
Publicado: (2020)

Lung fibrosis: an undervalued finding in COVID-19 pathological series
por: Grillo, Federica, et al.
Publicado: (2021)

Covid-19 during pregnancy: A case series from an universally tested population from the north of Portugal
por: Dória, Mariana, et al.
Publicado: (2020)

Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy
por: Altaf, Farwa, et al.
Publicado: (2021)

Fibrinolytic therapy for parapneumonic empyema during pregnancy
por: Ulutas, Hakki, et al.
Publicado: (2011)

VATS and Intrapleural Fibrinolytic Therapy for Parapneumonic Empyema
por: Ohara, Gen, et al.
Publicado: (2018)

Efficacy of standardizing fibrinolytic therapy for parapneumonic effusion
por: James, Charles A., et al.
Publicado: (2022)

Impaired Fibrinolytic Potential Predicts Oxygen Requirement in COVID-19
por: Wang, Julie, et al.
Publicado: (2022)

Therapeutics targeting the fibrinolytic system
por: Lin, Haili, et al.
Publicado: (2020)

Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
por: Kim, Hye-Jin, et al.
Publicado: (2014)

Infective endocarditis in obstructive hypertrophic cardiomyopathy: a case series and literature review
por: Wu, Zi-Wen, et al.
Publicado: (2021)

The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective
por: Kwaan, Hau C., et al.
Publicado: (2021)

Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines Against COVID-19 Hospitalizations: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

The association between blood pressure levels and mortality in critically ill patients with COVID-19 in Wuhan, China: a case-series report
por: Geng, Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5ji7kggblvkmmv3uk8n699t3th